clioquinol has been researched along with 2-phenylbenzothiazole in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.67) | 29.6817 |
| 2010's | 23 (76.67) | 24.3611 |
| 2020's | 5 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bush, AI; Fraser, BH; Greguric, I; Han, Y; Krause-Heuer, AM; Lewis, R; Liang, SH; Shoup, TM; Southon, AG; Vasdev, N; Volitakis, I; Zhang, B | 1 |
| Doraiswamy, PM; Xiong, GL | 1 |
| Ames, D; Batsman, S; Blennow, K; Bush, AI; Harrison, J; Lannfelt, L; Masters, CL; Murdoch, R; Ritchie, CW; Targum, S; Wilson, J; Zetterberg, H | 1 |
| Bedo, J; Blennow, K; Bush, AI; Cummings, JL; Faux, NG; Gunn, A; Harrison, J; Herd, CM; Ingelsson, M; Lannfelt, L; Masters, CL; Rembach, A; Ritchie, CW; Tanzi, RE; Tsatsanis, A; Zetterberg, H | 1 |
| Shoji, M | 1 |
| Barnham, KJ; Kenche, VB | 1 |
| Adlard, PA; Bica, L; Bush, AI; Cappai, R; Crouch, PJ; Donnelly, PS; Filiz, G; Finkelstein, DI; Nurjono, M; White, AR | 1 |
| Adlard, PA; Barnham, KJ; Bush, AI; Cherny, RA; Crouch, PJ; Donnelly, PS; Greenough, MA; Hung, LW; Masters, CL; Mot, AI; Parker, SJ; Savva, MS; Volitakis, I; White, AR | 1 |
| Faller, P | 1 |
| Jenagaratnam, L; McShane, R; Sampson, EL | 2 |
| Barnham, KJ; Bush, AI; Cherny, RA; Kenche, VB; Link, CD; Masters, CL; McColl, G; Pukala, TL; Roberts, BR; Roberts, CM; Ryan, TM | 1 |
| Adlard, PA; Bray, L; Bush, AI; Cherny, RA; Doble, P; Finkelstein, DI; Gunawan, L; Hare, D; Lear, J; Sedjahtera, A | 1 |
| Ayton, S; Bush, AI; Cherny, RA; Finkelstein, DI; Massa, SM; McColl, G | 1 |
| Langbehn, DR | 1 |
| Adlard, PA; Bush, AI; Doble, P; Finkelstein, DI; Hare, D; James, S; Lal, V; Parncutt, J | 1 |
| Barnham, KJ; Donnelly, PS; Hill, AF; Johanssen, T; Liu, XM; Petrou, S; Suphantarida, N | 1 |
| Adlard, PA; Barnham, KJ; Curtain, CC; Doble, PA; Hare, DJ; Hinds, MG; Kirby, N; Li, QX; Lind, M; Masters, CL; McColl, G; Mertens, HD; Pham, CL; Roberts, AM; Roberts, BR; Ryan, TM | 1 |
| Bharti, K; Majeed, AB; Prakash, A | 1 |
| Fu, CL; Hsu, LS; Hu, MK; Liao, YF | 1 |
| Adlard, PA; Barnham, KJ; Bray, L; Bush, AI; Chan, J; Cherny, RA; Finkelstein, DI; Gunawan, L; Hung, LW; Liu, XM; Okamura, N; Parsons, J; Sedjahtera, A; Villemagne, VL; Yanai, K | 1 |
| Bohlmann, L; Brazel, EB; Cook, GM; Cork, AJ; Davies, MR; De Oliveira, DMP; Dougan, G; El-Deeb, IM; Ferguson, SA; Harbison-Price, N; McDevitt, CA; McEwan, AG; Nimmo, GR; Ong, CY; Phan, MD; Rivera-Hernandez, T; Schembri, MA; Soderholm, AT; von Itzstein, M; Walker, MJ | 1 |
| Cao, M; Feng, X; Wang, W; Wang, Z; Xiang, H; Yang, X | 1 |
| El-Deeb, IM; Everest-Dass, AV; Haselhorst, T; Jen, FE; Jennings, MP; Singh, S; von Itzstein, M; Walker, MJ | 1 |
| Ge, S; Guyatt, G; Lu, L; Tang, C; Wang, S; Wen, H; Xu, M; Xu, N; Yao, G; Zeng, J; Zhang, Y; Zheng, X | 1 |
| George, GN; Harris, HH; Millhauser, GL; Pickering, IJ; Roseman, GP; Sopasis, GJ; Summers, KL | 1 |
| Bohlmann, L; Brazel, EB; Cunningham, BA; De Oliveira, DMP; Eijkelkamp, BA; El-Deeb, IM; Ganio, K; Iverson, AR; Keller, B; Maher, MJ; McDevitt, CA; McEwan, AG; Neville, SL; Rosch, JW; Sikanyika, M; Tan, A; Udagedara, SR; von Itzstein, M; Walker, MJ | 1 |
| Dolgova, NV; George, GN; Harris, HH; Kroll, T; Millhauser, GL; Pickering, IJ; Pushie, MJ; Roseman, G; Schilling, KM; Sokaras, D; Summers, KL | 1 |
6 review(s) available for clioquinol and 2-phenylbenzothiazole
| Article | Year |
|---|---|
Pharmacological strategies for the prevention of Alzheimer's disease.
Topics: Alzheimer Disease; Clioquinol; Drug Delivery Systems; Humans; Pharmaceutical Preparations | 2006 |
[Drug therapy for Alzheimer's disease].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Clioquinol; Drug Design; Excitatory Amino Acid Antagonists; Flurbiprofen; Indoles; Memantine; Meta-Analysis as Topic; Randomized Controlled Trials as Topic | 2010 |
Alzheimer's disease & metals: therapeutic opportunities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Cations; Clinical Trials as Topic; Clioquinol; Coordination Complexes; Copper; Humans; Oxidative Stress; Protein Binding; Synapses; Zinc | 2011 |
Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Topics: Aged; Alzheimer Disease; Chelating Agents; Clioquinol; Humans; Randomized Controlled Trials as Topic | 2012 |
Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Chelating Agents; Clioquinol; Humans; Randomized Controlled Trials as Topic | 2014 |
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
Topics: Acitretin; Alanine; Alzheimer Disease; Amyloid beta-Peptides; Antibodies, Monoclonal, Humanized; Anxiety; Azepines; Clioquinol; Copper; Cyclic S-Oxides; Depression; Diarrhea; Exanthema; Fatigue; Flurbiprofen; Humans; Immunoglobulins, Intravenous; Inositol; Mental Status and Dementia Tests; Minimal Clinically Important Difference; Orotic Acid; Oxadiazoles; Severity of Illness Index; Sulfonamides; Syncope; Thiadiazines; Treatment Outcome; Vomiting | 2020 |
3 trial(s) available for clioquinol and 2-phenylbenzothiazole
| Article | Year |
|---|---|
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Clioquinol; Dose-Response Relationship, Drug; Double-Blind Method; Down-Regulation; Female; Humans; Ionophores; Male; Metals; Middle Aged; Peptide Fragments; Placebo Effect; Quinolines; Safety; Treatment Outcome | 2008 |
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Area Under Curve; Australia; Clioquinol; Cognition Disorders; Copper; Dose-Response Relationship, Drug; Double-Blind Method; Executive Function; Humans; International Cooperation; Ionophores; Neuropsychological Tests; Peptide Fragments; ROC Curve; Superoxide Dismutase; Superoxide Dismutase-1; Sweden; tau Proteins | 2010 |
Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Biomarkers; Clioquinol; Cognition Disorders; Double-Blind Method; Female; Humans; Huntington Disease; Male; Middle Aged; Placebos; Treatment Outcome | 2015 |
21 other study(ies) available for clioquinol and 2-phenylbenzothiazole
| Article | Year |
|---|---|
Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease.
Topics: | 2015 |
Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cells, Cultured; Clioquinol; Dendritic Spines; Disease Models, Animal; Female; Hippocampus; Ionophores; Memory; Metals; Mice; Mice, Transgenic; Nerve Tissue Proteins; Neurites; Neurogenesis; Synapses | 2011 |
The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Blotting, Western; Calcineurin; Calcineurin Inhibitors; Caspase 3; Cell Line, Tumor; Clioquinol; Copper; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Humans; Mass Spectrometry; Matrix Metalloproteinase 2; Metals; Molecular Chaperones; Peptide Hydrolases; Phosphorylation; Zinc | 2011 |
Copper in Alzheimer disease: too much, too little, or misplaced?
Topics: Alzheimer Disease; Animals; Brain; Clioquinol; Copper; Hepatolenticular Degeneration; Humans; Menkes Kinky Hair Syndrome | 2012 |
Utility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Clioquinol; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Neuroprotective Agents | 2012 |
Can we reverse Alzheimer's? New approaches from Harvard offer hope.
Topics: Alzheimer Disease; Clioquinol; Cognition; Health Behavior; Humans; Mental Processes; Risk Reduction Behavior; Task Performance and Analysis | 2013 |
A novel approach to rapidly prevent age-related cognitive decline.
Topics: Aging; Animals; Behavior, Animal; Biomarkers; Cell Count; Clioquinol; Cognition Disorders; Dendritic Spines; Female; Glutamic Acid; Hippocampus; Maze Learning; Mice; Mice, Inbred C57BL; Neurogenesis; Neuronal Plasticity; Protein Phosphatase 2; Receptors, Glutamate; Synapses; Vesicular Glutamate Transport Protein 1; Zinc | 2014 |
PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease.
Topics: Animals; Atrophy; Caenorhabditis elegans; Clioquinol; Corpus Striatum; Disease Susceptibility; Dose-Response Relationship, Drug; Drug Resistance; Huntington Disease; Longevity; Mice; Mice, Transgenic; Motor Skills; Species Specificity | 2012 |
Criteria for success in safety and tolerability trials.
Topics: Clioquinol; Cognition Disorders; Female; Humans; Huntington Disease; Male | 2015 |
Metal chaperones prevent zinc-mediated cognitive decline.
Topics: Analysis of Variance; Animals; Carrier Proteins; Cation Transport Proteins; Clioquinol; Cognition Disorders; Disease Models, Animal; Escape Reaction; Female; Gene Expression Regulation; Hippocampus; In Vitro Techniques; Long-Term Potentiation; Male; Maze Learning; Membrane Proteins; Membrane Transport Proteins; Mice; Mice, Knockout; Patch-Clamp Techniques; Zinc | 2015 |
PBT2 inhibits glutamate-induced excitotoxicity in neurons through metal-mediated preconditioning.
Topics: Animals; Animals, Newborn; Calcineurin; Cerebral Cortex; Clioquinol; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Embryo, Mammalian; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Glycogen Synthase Kinase 3; Memantine; Metals; Mice; Mice, Inbred C57BL; Neurons; Time Factors | 2015 |
Stabilization of nontoxic Aβ-oligomers: insights into the mechanism of action of hydroxyquinolines in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzothiazoles; Biophysics; Caenorhabditis elegans; Cells, Cultured; Cerebral Cortex; Chromatography, Gel; Clioquinol; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxyquinolines; Mice; Microscopy, Electron; Neurons; Peptide Fragments; Protein Binding; Scattering, Small Angle; Thiazoles | 2015 |
Possible role of metal ionophore against zinc induced cognitive dysfunction in D-galactose senescent mice.
Topics: Administration, Oral; Aging; Amyloid beta-Peptides; Animals; Clioquinol; Cognition Disorders; Dose-Response Relationship, Drug; Galactose; Injections, Subcutaneous; Male; Mice; Mice, Inbred Strains; Zinc Sulfate | 2016 |
New Hydroxyquinoline-Based Derivatives as Potent Modulators of Amyloid-β Aggregations.
Topics: Amyloid beta-Peptides; Chelating Agents; Clioquinol; Copper; Hydroxyquinolines; Protein Aggregation, Pathological; Structure-Activity Relationship; Zinc | 2016 |
Targeting metals rescues the phenotype in an animal model of tauopathy.
Topics: Animals; Clioquinol; Female; Male; Memory; Mice; Spatial Learning; Tauopathies | 2018 |
Chemical Synergy between Ionophore PBT2 and Zinc Reverses Antibiotic Resistance.
Topics: Anti-Bacterial Agents; Clioquinol; Drug Resistance, Bacterial; Drug Synergism; Gram-Positive Bacteria; Ionophores; Microbial Sensitivity Tests; Zinc | 2018 |
WBQ5187, a Multitarget Directed Agent, Ameliorates Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease and Modulates Cerebral β-Amyloid, Gliosis, cAMP Levels, and Neurodegeneration.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anesthetics, General; Animals; Benzofurans; Biological Availability; Blood-Brain Barrier; Brain Chemistry; Clioquinol; Cyclic AMP; Disease Models, Animal; Drug Evaluation, Preclinical; Gliosis; Hippocampus; Male; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nausea; Neuroprotective Agents; Phosphodiesterase 4 Inhibitors; Resorcinols; Second Messenger Systems; Vomiting | 2019 |
Topics: Anti-Bacterial Agents; Clioquinol; Colistin; Drug Synergism; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Polymyxin B | 2020 |
Copper(II) Binding to PBT2 Differs from That of Other 8-Hydroxyquinoline Chelators: Implications for the Treatment of Neurodegenerative Protein Misfolding Diseases.
Topics: Alzheimer Disease; Animals; Chelating Agents; Clioquinol; Coordination Complexes; Copper; Density Functional Theory; Humans; Ligands; Molecular Structure; Neuroprotective Agents; Proteostasis Deficiencies; X-Ray Absorption Spectroscopy | 2020 |
Dysregulation of Streptococcus pneumoniae zinc homeostasis breaks ampicillin resistance in a pneumonia infection model.
Topics: Ampicillin; Ampicillin Resistance; Animals; Anti-Bacterial Agents; Clioquinol; Disease Models, Animal; Female; Homeostasis; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pneumonia; Streptococcus pneumoniae; Zinc | 2022 |
Alzheimer's Drug PBT2 Interacts with the Amyloid β 1-42 Peptide Differently than Other 8-Hydroxyquinoline Chelating Drugs.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Chelating Agents; Clioquinol; Copper; Humans; Ions; Metals; Oxyquinoline; Peptide Fragments; Solvents; Zinc | 2022 |